Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Proiodamine is a small molecule organic iodine compound primarily used in ophthalmology to promote the absorption of pathological products in the eye. Developed and marketed by JiangSu WuZhong Pharmaceutical Development under the brand name Luo Guan, it is typically administered via intramuscular or subconjunctival injection. The drug functions by releasing iodine ions into the ocular tissues, which enhances local metabolism and blood circulation. This process facilitates the resolution and absorption of inflammatory exudates, vitreous opacities, and retinal or vitreous hemorrhages. It is commonly indicated for conditions such as chorioretinitis, vitreous opacity, and various forms of ocular hemorrhage.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on proiodamine.